13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q2 2019. See the latest, Q2 2026 →
Reported value
$5.27B
+172% on the quarter before
Positions
22
6 new · 1 sold out
Top 10
98.2%
of the value
Est. gain
−$197.9M
on stocks held all quarter
Est. return
−11.8%
on those stocks since Q1 2019
Positions as of Jun 30, 2019, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2019. Striped tiles are options.
Largest buys
Since Q1 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Uber~$3.30BNew · 0.0% → 62.6%+71,138,345 shares
- Slack Technologies Inc.~$454.0MNew · 0.0% → 8.6%+12,107,558 shares
- Cortexyme Inc~$19.3MNew · 0.0% → 0.4%+453,870 shares
- CrowdStrike~$9.6MNew · 0.0% → 0.2%+140,000 shares
- Mohawk Group Hldgs Inc~$8.5MNew · 0.0% → 0.2%+1,055,954 shares
- Ideaya Biosciences Inc~$7.5MNew · 0.0% → 0.1%+753,187 shares
Largest sells
Since Q1 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Arris Intl Inc~$240.3MSold out · 12.4% → 0.0%−7,603,500 shares
- Snap~$30.0MCut · 1.5% → 0.1%−2,094,838 shares
- Autolus Therapeutics Plc~$237,001Cut · 1.2% → 0.2%−14,720 shares
Holdings
As of Jun 30, 2019. Changes are in shares against Mar 31, 2019, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UberCOM · shares New | 62.6% | $3.30B | — | ||||||||
| Lyft IncCL A COM · shares 0% · price −16.1% | 16.0% | $843.0M | −$161.4M | ||||||||
| Slack Technologies Inc.COM CL A · shares New | 8.6% | $454.0M | — | ||||||||
| Jd Com IncSPON ADR CL A · shares 0% · price +0.5% | 7.8% | $410.5M | +$1.9M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price −10.4% | 0.93% | $49.3M | −$5.7M | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price −36.3% | 0.76% | $40.1M | −$22.9M | ||||||||
| Alector IncCOM · shares 0% · price +1.5% | 0.42% | $22.3M | +$329,000 | ||||||||
| DocuSignCOM · shares 0% · price −4.1% | 0.39% | $20.4M | −$876,000 | ||||||||
| Cortexyme IncCOM · shares New | 0.37% | $19.3M | — | ||||||||
| Dexcom IncCOM · shares 0% · price +403.2% | 0.31% | $16.6M | +$13.3M | ||||||||
| Forty Seven IncCOM · shares 0% · price −34.4% | 0.31% | $16.4M | −$8.6M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price −10.1% | 0.24% | $12.8M | −$1.4M | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares −2.1% · price −48.8% | 0.21% | $11.3M | −$10.7M | ||||||||
| Gritstone Oncology IncCOM · shares 0% · price −16.2% | 0.20% | $10.3M | −$2.0M | ||||||||
| CrowdStrikeCL A · shares New | 0.18% | $9.6M | — | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price +12.2% | 0.18% | $9.5M | +$1.0M | ||||||||
| Mohawk Group Hldgs IncCOM · shares New | 0.16% | $8.5M | — | ||||||||
| Ideaya Biosciences IncCOM · shares New | 0.14% | $7.5M | — | ||||||||
| SnapCL A · shares −80% · price +29.8% | 0.14% | $7.5M | +$1.7M | ||||||||
| Cloudera IncCOM · shares 0% · price −51.9% | 0.04% | $2.3M | −$2.4M | ||||||||
| BlockCL A · shares 0% · price −3.2% | 0.02% | $895,000 | −$30,000 | ||||||||
| Dropbox IncCL A · shares 0% · price +14.8% | 0.01% | $326,000 | +$42,000 | ||||||||
| Total · 22 positions | 100% | $5.27B | −$197.9M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2019 to Q2 2019: 16 stocks held throughout, down $197.9M (−11.8%).
- Dexcom Inc+$13.3M+403%
- Jd Com Inc+$1.9M+0%
- Snap+$1.7M+30%
- Evelo Biosciences Inc+$1.0M+12%
- Alector Inc+$329,000+1%
- Magenta Therapeutics Inc−$5.7M−10%
- Forty Seven Inc−$8.6M−34%
- Autolus Therapeutics Plc−$10.7M−49%
- Arcus Biosciences Inc−$22.9M−36%
- Lyft Inc−$161.4M−16%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |